



Press Release

Wednesday, April 08, 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE: STAR

Strides Arcolab receives NDA approval from USFDA for Lamivudine and Stavudine under PEPFAR scheme

Total PEPFAR approvals - 11

Strides Arcolab Limited (Strides) today announced that it has received tentative approval from the United States – Food and Drug Administration for one new drug application (NDA) for fixed dose combination of Lamivudine and Stavudine Tablets 150 mg / 30 mg under the expedited review provisions of the President’s Emergency Plan for AIDS Relief (PEPFAR).

V S Iyer, Chief Executive Officer – India Operations of Strides stated:

“This approval is yet another significant milestone in the front line of approvals for key HIV / AIDS medicines. This takes the total NDAs / ANDAs approvals received to 11 under the PEPFAR program. This, combined with our pipeline of second line drugs will make us a significant player in the quality, affordable multi-source ARVs business segment.”

The company supplies ARV products to global procurement agencies and this approval adds to the overall basket of medicines available.

About Strides Arcolab Limited

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penems, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures

and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company's website at www.stridesarco.com

<p>For further information, please contact Mr. Arun Kumar, Group CEO Tel: +91-80-6658 0118</p> <p>Mr.V S Iyer, CEO - India Operations Tel: +91-80-6658 0111</p>	<p>Mahesh Nair Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in</p> <p>Kasturi Wasmatar Corporate Voice/ Weber Shandwick Mobile: +91 99167 28393 Email: kasturi@corvoshandwick.co.in</p>
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------